The cholesterol challenge(s) in cardiovascular risk in 2014
|
|
- Hilary Dennis
- 5 years ago
- Views:
Transcription
1 The cholesterol challenge(s) in cardiovascular risk in 2014 Alberto Zambon University of Padova - Italy
2 Italy
3 University of Padova The Oldest Medical School in the World (established in a.d. 1222)
4 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions The priority of dyslipidemia treatment is LDL-C management It is time to forget LDL targets? (US vs EU, SA,NZ,AU) In Europe we (GPs, Specialists) also believe that: Elevated TG and/or low HDL-C have no clinical value when LDL-C is on target Non HDL-C: clinically useless, LDL-C it s enough! Fibrates in combination with statin therapy have not demonstrated CV event reduction and safety is a concern! Is there any perception that: Fibrates can do more that other lipid modifying agents
5 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions PERCEPTION The priority of dyslipidemia treatment is LDL-C management 1. True 2. False
6 Reduction in Event Rate (%) Reduction in Event rate (%) Lancet 2005; 366: Reduction in incidence of major coronary and cardiovascular events and mean absolute LDL-C reduction (Meta-analysis of 14 trials, n=90.056, ) 50 Major Coronary Events 50 Major Cardiovascular Events Lp(a ) Reduction in LDL-C (mmol/l) -10 Reduction in LDL-C (mg/dl) -23% every 1 mmol/l LDL-C -21% every 1 mmol/l LDL-C
7 CORRIERE DELLA SERA Thursday November 14 th Cholesterol: Not a problem! - Pills only for very high levels!
8 Effect of Treatment in Patients with HoFH Cardiovascular morbidity and mortality characteristics of patients with Homozygous FH before and after the advent of statins (1990) yrs yrs yrs *P< P<0.001 P<0.01 MACE indicates major adverse cardiac event; MIs, myocardial infarctions; CABG, coronary artery bypass surgery; AVR, aortic valve replacement; PTCA, percutaneous coronary angioplasty; and TIA, transient ischemic attack. Raal et al Circulation 2011;124:
9
10 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions LDL-C #1 priority to reduce risk of CVD events: TRUE
11 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice PERCEPTION It is time to forget LDL targets? (US vs EU, SA, AU,NZ) 1. True 2. False
12 SIMILARITIES AND DIFFERENCES 2011 ESC-EAS Management of Dyslipidaemias Guidelines vs 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk EAS/ESC 1 AHA/ACC 2 SECONDARY PREVENTION PRIMARY PREVENTION LDL > 4.9 mmol/l PRIMARY PREVENTION IN DIABETES PRIMARY PREVENTION HIGH RISK Target LDL-C < 1.8 mmol/l, or at least 50% reduction. If target cannot be reached with statin, drug combination may be considered. Target LDL-C < 2.5 mmol/l. If target cannot be reached maximal reduction of LDL-C, using appropriate drug combinations in tolerated doses. Diabetes with other risk factors or organ damage: Target LDL-C = 1.8 mmol/l, or at least 50% reduction. Uncomplicated diabetes: Target LDL < 2.5 mmol/l. SCORE = 5% risk of fatal CVD: Target <2.5 mmol/l. High-intensity statin. If 50% reduction is not reached drug combination may be considered. High-intensity statin therapy, aimed at achieving at least 50% reduction of LDL-C. If 50% reduction cannot be achieved, consider additional therapy. Diabetes with high risk: High-intensity statin therapy. Diabetes with low risk: Moderate-intensity statin therapy. Total risk for CVD event >7.5%: Moderate- to high-intensity statin therapy. Risk 5-7.5% risk of CVD event: moderate-intensity statin therapy. Shared emphasis on the importance of LDL-C lowering in cardiovascular prevention Very similar view on which high risk groups should be the targets for drug treatment No LDL-C Targets (AHA/ACC) Intensity of Statin therapy as goal of treatment (AHA/ACC) 1 EAS/ESC Guidelines European Heart Journal (2011) 32, Stone NJ et al Circulation. 2013, doi: /01.cir a
13 Major CV Events in 5 Large Trials Comparing Intensive-Dose to Moderate-Dose Statin Therapy Meta-Analysis Cases Total No (%) Intensive Dose Moderate Dose Incident CVD PROVE-IT TIMI /1707(18.4) 355/1688 (21) 0.85 A to Z 212/1768 (12) 234/1736 (13.5) 0.87 TNT 647/3798 (17) 830/3797 (24.6) 0.73 IDEAL 776/3737 (20.8) 917/3724 (24.6) 0.80 SEARCH 1184/5398 (21.9) 1214/5399 (22.5) 0.97 Pooled odd ratio 3134/16408 (19.1) 3550/16344 (21.7) 0.84 Intensive vs Moderate LDL-C mmol/l Intensive vs Moderate= Odds Ratio (95% CI) 16% CV Events Preiss D. et al. JAMA. 2011;305(24):
14 LDL-C mmol/l LDL-C mmol/l Adherence to statin last three months Intervention to Improve Adherence to Lipid-Lowering Medication and Lipid-Levels in Patients With High CVD Risk C Adherence to lipid-lowering medication Patients n=2500, from Amsterdam, The Netherlands, age 49,2 yrs, 52% primary prevention, BMI 28,1 RC: routine care (blue circles), Nurse counselling once/year, lipid profile at 3, 9, 18 month, no LDL-C targets EC: extended care (red triangles) Nurse counselling four times year, lipid profile at 3, 9, 18 month, yes LDL-C targets Months from start intervention 5 Primary CVD Prevention 5 Secondary CVD Prevention * p<0.01 * * Months from start intervention Months from start intervention Nieuwkerk PT et al. Am J Cardiol 2012;110:
15 The Importance of Monitoring Measures to improve adherence are inseparably bound to achievement of the clinical goals for which the drugs are prescribed. For cardiovascular disease, perhaps the most clinically relevant of these are the regular measurement of serum lipids. Haynes RB et al. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD DOI: / CD000011
16 SIMILARITIES AND DIFFERENCES 2011 ESC-EAS Management of Dyslipidaemias Guidelines vs 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk EAS/ESC 1 AHA/ACC 2 SECONDARY PREVENTION PRIMARY PREVENTION LDL > 4.9 mmol/l PRIMARY PREVENTION IN DIABETES PRIMARY PREVENTION HIGH RISK Target LDL-C < 1.8 mmol/l, or at least 50% reduction. If target cannot be reached with statin, drug combination may be considered. Target LDL-C < 2.5 mmol/l. If target cannot be reached maximal reduction of LDL-C, using appropriate drug combinations in tolerated doses. Diabetes with other risk factors or organ damage: Target LDL-C = 1.8 mmol/l, or at least 50% reduction. Uncomplicated diabetes: Target LDL < 2.5 mmol/l. SCORE 5% risk of fatal CVD: Target <2.5 mmol/l. High-intensity statin. If 50% reduction is not reached drug combination may be considered. High-intensity statin therapy, aimed at achieving at least 50% reduction of LDL-C. If 50% reduction cannot be achieved, consider additional therapy. Diabetes with high risk: High-intensity statin therapy. Diabetes with low risk: Moderate-intensity statin therapy. Total risk for CVD event >7.5%: Moderate- to high-intensity statin therapy. Risk 5-7.5% risk of CVD event: moderate-intensity statin therapy. Impact on Population in Primary Prevention (AHA/ACC vs EAS/ESC) 1 EAS/ESC Guidelines European Heart Journal (2011) 32, Stone NJ et al Circulation. 2013, doi: /01.cir a
17 JAMA 2014;311(14): subjects from the Rotterdam Study age >65 yrs, primary prevention ON STATIN THERAPY Females Males Males ACC/AHA vs ATP III and ESC: ACC/AHA recommend statin therapy for more adults who would be expected to have future cardiovascular events (higher sensitivity) but would also include many adults who would not have future events (lower specificity).
18 online publish-ahead-of-print 17 March 2014
19 online publish-ahead-of-print 17 March 2014 The ACC/AHA 2013 guidelines Vs The ESC/EAS 2011 guidelines Abolition of LDL-C targets: - confusing for many physicians - detrimental for medication adherence and patient engagement in self-management Reduction in the threshold for treatment in primary prevention: - greater number of patients being prescribed statin - good in young patients with high life time risk - very large number of older patients offered therapy! Current Recommendation by ESC-EAS The ESC/EAS guidelines from 2011 seem to be the most wide ranging, pragmatic, and appropriate option for European countries In clinical practice maintain the use of LDL-C targets
20 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions LDL-C #1 priority to reduce risk of CVD events: TRUE It is time to forget LDL targets (US vs EU, AU, SA): QUESTIONABLE
21 (Mis) Perceptions in Dyslipidaemia: Evidence Applied to Everyday Practice In Europe we (GPs and Specialists) also believe that: PERCEPTION Elevated TG and/or low HDL-C have NO clinical value when LDL-C is on target 1. True 2. False
22 Relative cardiovascular risk reduction* (%) 30-day risk of death, MI or recurrent ACS (%) PROVE IT-TIMI 22: Reaching target LDL alone with statin therapy does not achieve maximal CV risk reduction if TGs are raised For people at target LDL, those with low TGs have an additional 12% reduction in cardiovascular risk versus those with raised TGs LDL 1.8 TG 1.7 0% LDL <1.8 TG % LDL <1.8 TG <1.7 LDL and TG in mmol/l PROVE IT-TIMI 22 study TG +56% p= % -28% p=0.017 vs reference group (LDL 1.8, TG 1.7) <2.2 (n=603) (n=2,796) On-treatment TG mmol/l in patients with LDL-C <1.8 mmol/l LDL-C <70 mg/dl= 1.8 mmol/l TG <150 mg/dl= 1.7 mmol/l, TG 200 mg/dl= 2.2 mmol/l *Based on combined endpoint of overall mortality, myocardial infarction or hospitalisation due to recurring ACS ACS, acute coronary syndrome; CV, cardiovascular; LDL, low-density lipoprotein; TG, triglyceride Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51:
23 5 y risk of MCVEs (%) MCVE Frequency by HDL-C level in group with LDL-C < 70 mg/dl (1.8 mmol/l) HR (95% CI) vs Q1 Q ( ) Q ( ) Q ( ) Q ( ) + 39 % Q1 Q2 Q3 Q4 Q5 0 (<37) [0.96] (37-42) [ ] * HDL-C at month 3 of the double-blind treatment phase (42-47) [ ] (47-55) [ ] Quintile of HDL-C* (mg/dl) [mmol/l] (>55) [1.42] Barter et al. N Engl J Med 2007; 357:
24 % of events ACCORD-Lipid Study Residual Risk on Statin* (Placebo Group) Previous CVD Lipid Sub-groups Overall Yes No TG 2.3 and HDL 0.9 HDL 0.9 % events = non fatal MI, non fatal stroke, CV death (follow-up : 4.7 years) * LDL-C 2.0 mmol/l on Simvastatin (mean dose 22 mg) ACCORD Study Group. NEJM 2010; 362: TG 2.3 TG<2.3 and HDL>0.9
25 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions LDL-C #1 priority to reduce risk of CVD events: TRUTH It is time to forget LDL targets (US vs AU,NZ,EU): QUESTIONABLE In Europe we (GPs) also believe that: Elevated TG and/or low HDL-Chave HAVE no CLINICAL clinical value VALUE when when LDL-C LDL-C is on target is on target : FALSE : HIGH CV RESIDUAL RISK
26 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice PERCEPTION Non HDL-C: clinically useless LDL-C it s enough! 1. True 2. False
27 Non-HDL Cholesterol HDL LDL IDL VLDL Anti Atherogenic Lipoproteins Atherogenic Lipoproteins Non HDL-C= total Cholesterol-HDL-C
28 Non-HDL-C and Apo B in Diabetes- Guidelines APO B NON-HDL Cholesterol HDL LDL IDL VLDL Lp(a) NON-HDL C Secondary goal: NZ/AU, ADA EAS/ESC Inexpensive, easy to calculate: Total cholesterol HDL-C Target levels easy to remember: Non HDL-C goals: LDL-C goal mmol/l European Heart Journal (2011) 32, Better CV predictor than LDL-C in diabetics since it takes into account all the atherogenic lipids!!!
29 Association of LDL-C, Non HDL Cholesterol, and Apo B With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis patients enrolled in 8 trials published between 1994 and 2008 Risk of Major Cardiovascular Events by LDL and non-hdl Cholesterol Categories +32% Data markers indicate hazard ratios (HRs) and 95% CIs for risk of major cardiovascular events. Results are shown for 4 categories of statin-treated patients based on whether or not they reached the LDL-C target of 100 mg/dl (2.6 mmol)l) and the non HDL-C target of 130 mg/dl (3.4 mmol/l). HRs were adjusted for sex, age, smoking, diabetes, systolic blood pressure, and trial. Boekholdt M et al. JAMA. 2012;307(12):
30 Non-HDL Cholesterol HDL LDL IDL VLDL At Target <2.6 mmol/l Triglycerices Anti Atherogenic Lipoproteins Non HDL-C= >3.4 mmol/l NOT AT TARGET Atherogenic Lipoproteins Non-HDL cholesterol: emerging as #1 TARGET for treatment of Residual Cardiovascular Risk
31 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions LDL-C #1 priority to reduce risk of CVD events: TRUE It is time to forget LDL targets (US vs EU): QUESTIONABLE In Europe we also believe that: Elevated TG and/or low HDL-C HAVE CLINICAL VALUE when LDL-C is on target : HIGH CV RESIDUAL RISK Non HDL-C: clinically emerging useless #1 TARGET, LDL-C for it s CV enough! (Residual) FALSERisk
32 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice PERCEPTION Fibrates in combination with statin therapy have not demonstrated CV event reduction and safety is a concern! 1. True 2. False
33 Mean % change from baseline to 12 weeks (mg/dl) Mean % change from baseline to 12 weeks (mg/dl) Adding Fenofibric Acid* to a moderate-dose statin improved the three key lipids vs. monotherapy Randomisation 2,715 patients with mixed dyslipidaemia : LDL-C 3.4 mmol/l, TG 1.7 mmol/l and HDL-C <1.0 for men and <1.3 mmol/l for women Feno + low-dose statin*: pooled results through 12 weeks HDL-C TG LDL-C p< % +9% -5% Moderate-dose statin Feno + Moderate-dose statin Fenofibric acid -24% p< % p< % *Moderate-dose statins included in study: simvastatin 40 mg, atorvastatin 40 mg and rosuvastatin 20 mg *Bioequivalent to 145 mg of fenofibrate Jones PH et al. J Clin Lipidol. 2010;3(2):
34 Major Cardiovascular Events (%) ACCORD Pre-specified subgroup analysis Patients with Elevated TG and Low HDL-C - Similar selection criteria -Same lipid-lowering therapy: simvastatin mg -Same LDL-C on therapy: 2.0 mmol/l Simvastatin Simvastatin + Fenofibrate High TG/Low HDL-C subgroup had 70% higher event rate +70% Small, dense LDL % RRR 4.95% ARR p= NNT=20 Triglycerides VLDL-TG 5 HDL-C 0 All Others in ACCORD 82.4% (n=4548) of the entire cohort High TG ( 2,3 mmol/l) and Low HDL-C ( 0,88 mmol/l) 17.6% (n=941) of the entire cohort **Major CV events defined as CV death, nonfatal MI and nonfatal stroke ACCORD Study Group. N Engl J Med March 14, Epub. Elam M, Lovato L, Ginsberg H. Clinical Lipidology 2011;6:9-20
35 Bruckert E et al J Cardiovasc PharmacolT 57:267, 2011 Sacks FM et al. N Engl J Med 2010 Effect of fibrates in subgroups without (A) and with (B) dyslipidemia A total of 2428 fibrate-treated subjects (302 events) and 2298 placebo-treated subjects (408 events) with dyslipidemia were included in the analysis B Subgroups with Dyslipidemia Study ACCORD FIELD BIP HHS VA-HIT Odds Ratio (95% CI) 31% 27% 39% 78% 28% A Complementary Subgroups Study Odds Ratio (95% CI) ACCORD FIELD BIP HHS VA-HIT Summary 0.65 ( ) % Summary 0.94 ( ) % ACCORD lipid criteria TG 2.30 mmol/l, HDL-C 0.88 mmol/l Fibrate treatment reduce CVD among patients with atherogenic dyslipidemia
36 CV Risk Reduction by Baseline non-hdl-c in ACCORD Lipid Patients Receiving a Statin at Baseline Baseline Non-HDL-C and LDL-C Hazard ratio (95% CI) Fenofibratesimvastatin monotherapy Simvastatin % with events (N) Withingroup p value Non-HDL-C 3.4 mmol/l LDL-C < 2.6 mmol/l 8.8 (217) 16.3 (196) Non-HDL-C 130 mg/dl LDL-C < 100 mg/dl Fenofibrate better Control better Source: Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm htm
37 Concerns regarding statin-fibrate use Adverse pharmacokinetic interactions Idiosyncratic drug interactions Major potential adverse drug effects: Myopathy and rhabdomyolysis Hepatic dysfunction Renal impairment and renal failure Pancreatitis
38 Statin-fibrate pharmacokinetic interactions Gemfibrozil Fenofibrate Atorvastatin C max increase expected No effect Simvastatin C max increase 2-fold No effect Pravastatin C max increase 2-fold No effect Rosuvastatin C max increase 2-fold No effect Fluvastatin No effect No effect Lovastatin C max increase 2.8-fold Not available
39 Mean plasma concentration-time profiles of simvastatin following multiple oral doses of 80 mg SIMVASTATIN with or without multiple oral doses of FENOFIBRATE (n = 22) and GEMFIBROZIL (n=21) Plasma Concentration (ng/ml) Simvastatin without fenofibrate Simvastatin with fenofibrate Simvastatin with gemfibrozil Time (hr) A.J. Bergman et al., Journal of Clinical Pharmacology 2004;44:
40 ACCORD Lipid: adverse event profile Adverse event Fenofibrate + simvastatin (20-40mg) (n=2,765) Placebo + simvastatin (20-40mg) (n=2,753) p-value Any gall bladder-related event 0.3% 0.2% 0.57 DVT/PE ALT ever >3xULN 1.9% 1.5% 0.21 ALT ever >5xULN 0.6% 0.2% 0.03 CPK ever >5xULN 1.9% 2.2% 0.43 CPK ever >10xULN 0.4% 0.3% 0.83 Any myopathy / myositis / rhabdomyolysis serious AE 0.1% 0.1% 1.00 Serum creatinine elevation Women ever >1.3 mg/dl 235 (28%) 157 (19%) <0.001 Men ever >1.5 mg/dl 698 (37%) 350 (19%) <0.001 Adapted from Ginsberg et al, DVT = deep venous thrombosis; PE = pulmonary embolism; ALT = alanine aminotransferase; CPK = creatinine phosphokinase; ULN = upper limit of normal. To convert values for serum creatinine from mg/dl to micromol/l, multiply by Randomised controlled trial (ACCORD-Lipid) comparing simvastatin + placebo versus simvastatin + fenofibrate (145mg bioequivalent 2 ) on major CV events in patients with type 2 diabetes over 4.7 years (mean). 1 Ginsberg HN, et al. NEJM 2010;362: :supplementary appendix 1
41 Mean (95% CI) Plasma Creatinine (umol/l) Mean egfr (ml/min m -2 ) Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Davis TME, Ting R, Keech AC et al. Diabetologia 2011;54: On average umol/l Higher than (p<0.01) Fenofibrate -1.9 ml min Placebo -6.9 ml min Time from randomization (months) of renal function Values are mean (95% CI); p=0.0003; p=0.065; p< Fenofibrate Placebo 5.0 ml min egrf better on Fenofibrate Acute reversible changes in plasma creatinine Longer term egfr preservation in type 2 diabetes (mostly evident after treatment withdrawal) No evidence to date of permanent renal injury Fenofibrate reduces albuminuria progression and may reduce loss
42 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice Global (mis)perceptions LDL-C #1 priority to reduce risk of CVD events: TRUE It is time to forget LDL targets (US vs EU): QUESTIONABLE In Europe we also believe that: Elevated TG and/or low HDL-C HAVE CLINICAL VALUE when LDL-C is on target : HIGH CV RESIDUAL RISK Non HDL-C: emerging #1 TARGET for CV (Residual) Risk Fenofibrate Fibrates in combination with with statin simvastatin have not has demonstrated CV further event reduction, CV event safety reduction is a concern! in patients BOTH with FALSE diabetes and high TG/low HDL-C Safety of fenofibrate-statin combination is NOT A BARRIER
43 The Cholesterol Challenges in 2014: Evidence Applied to Everyday Practice PERCEPTION We (GPs) also believe that: Fibrates can do more than other lipid modifying agents 1. True 2. False
44 Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes 1 Diabetic Retinopathy Almost everyone with type 1 diabetes and over 60% of people with type 2 diabetes will be affected 2,3 Diabetic Nephropathy About half of patients develop microalbuminuria at some point 4 Diabetic Neuropathy Patients with diabetes have a 30-50% lifetime risk of developing chronic peripheral neuropathy 4 1. Negi A, Vernon SA. J R Soc Med. 2003;96(6): Klein R et al. Ophthalmology. 2008;115: Klein R et al. Arch Ophthalmol. 1994;112(9): Marshall SM, Flyvbjerg A. BMJ. 2006;333(7566):
45 Development or progression of diabetic microvascular complications STENO 2 study: 13.3 yrs follow-up Intensive treatment: oral anti-diabetic therapy, antihypertensive, lipidlowering agents + diet and lifestyle program, after a mean follow-up of 13.3 years HbA1c= 7.7% Sys BP=140 mmhg Dias BP=74 mmhg LDL-C= 71 mg/dl (1.8) HDL-C=51 mg/dl (1.3) TG= 99 mg/dl (1.12) Gaede P et al. N Eng J Med 2008;358: NEUROPATHY NEPHROPATHY RETINOPATHY 25%: development of nephropathy 55%: progression of neuropathy 51%: progression of retinopathy
46 Effect of Fenofibrate on Diabetic Retinopathy Adjudicated data from FIELD Parameter Placebo Fenofibrate P NNT Total N of Patients First Laser for DR a No retinopathy Prior retinopathy % Reduction first laser treatment (P.0002) DR: diabetic retinopathy defined as laser treatment for proliferative retinopathy or macular edema or increase by >2 steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale; NNT number needed to treat. a Data are given as absolute event rates (%) Effect of Fenofibrate on Diabetic Retinopathy Data from ACCORD-Eye Parameter Placebo Fenofibrate P NNT Simva. Simvastatin Total N of Patients Progression of DR a No retinopathy Prior retinopathy % Reduction in the progression of DR (P.006) Similar to benefits seen on intensive glucose lowering approach DR diabetic retinopathy defined as 3-step progression of ETDRS grade or development of diabetic retinopathy requiring laser photocoagulation or vitrectomy NNT number needed to treat. a Data are given as absolute event rates (%) Am J Ophthalmol 2012;154:6 12.
47 Direct Effects of Fibrates on Retinal Inflammation and Angiogenesis Diabetic Rodent Model Fenofibrate PPAR alpha activation Diabetes Oxygen-induced Retinopathy Model Fenofibrate PPAR alpha activation INFLAMMATION NF-kB MCP-1 ICAM-1 Leukostasis VASCULAR PERMEABILITY ISCHEMIA HIF-1alpha VEGF MCP-1 ICAM-1 Vascular Permeability, Endothelial Cell migration & gross ANGIOGENESIS Adapted from Abcouver SF. Diabetes. 2013;62:36-38
48 PPARa Ligands Inhibit VEGF-Induced Corneal Neoangiogenesis in mice Fenofibrate at 200 mg/kg/day (d), WY14643 at 50 mg/kg/day (e), ETYA at 50 mg/kg/day (f), Bezafibrate at 400 mg/kg/day (g), or Gemfibrozil at 400 mg/kg/day (Panigrahy D, Folkman J et al. PNAS, Jan 22, 2008, 105:985-90)
49 Fenofibrate provides a systemic treatment option to reduce DR progression at early stages Fenofibrate is approved in Australia for use in patients with type 2 diabetes and existing retonopathy to reduce progression of DR The benefit of fenofibrate in patients with existing DR is achieve on top of glycemic, blood pressure and LDL-C control The benefit is independent of baseline lipid levels (LDL-C, HDL-C,TG) Unlike current standard therapy, laser treatment, fenofibrate is noninvasive and there is no risk of ocular side effects
50 TAKE HOME MESSAGE The Cholesterol Challenges Applied to Everyday Practice in 2014 LDL-C #1 priority to reduce risk of CVD events LDL-C targets help therapeutic adherence to achieve clinical goals Elevated TG and/or low HDL-C have clinical value when LDL-C is on target : HIGH CV RESIDUAL RISK Non HDL-C: emerging as #1 TARGET for CV Risk Reduction Fenofibrate in combination with simvastatin has demonstrated further CV event reduction in diabetes and high TG/low HDL-C Safety of fenofibrate-statin combination is NOT A BARRIER Fenofibrate is the only lipid modifying agent that reduces the progression of DR in type 2 diabetes patients with existing DR
Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationFibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr
Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationIl rischio residuo nella persona con diabete: come individuarlo e come trattarlo?
Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo? Alberto Zambon University of Padova - Italy DISCLOSURE - CONFLICT OF INTEREST Prof. A. Zambon reports having received grants,
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationUse of Subgroups to Rescue a Trial or Improve Benefit-Risk
1 Use of Subgroups to Rescue a Trial or Improve Benefit-Risk Martin King, Ph.D. Director, Statistics Global Pharmaceutical R&D, Abbott Abbott Park, IL USA 2 Disclaimer The opinions in this presentation
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More information2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March 2017 - Crowne Plaza, Dublin 2016 ESC Guidelines on Cardiovascular Risk and elevated lipids Carlos Brotons Sardenya Primary
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More information2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals
Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals Sudden and unexpected deaths in an adult population, Cape Town, South Africa, 2001-2005 1 Sudden and unexpected
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More information